Hemostasis Management News
-
The next evolution in blood vessel occlusion
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young woman that ...
-
Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device
Saranas, a company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, announced today that the U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414. Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding a vascular access ...
-
Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors. “Pam is a terrific addition to our Board,” said Mike Gaffney, Chief Executive Officer. “Her work leading the ...
-
Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The ...
-
Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
Revenue increases 13.6% (9.2% cc) as a result of the sustainable growth strategy, with advances in all divisions and regions Bioscience leads the growth with EUR 3,994 million of revenue (13.6%; 8.9% cc). Diagnostic and Hospital continue to make progress with sales of EUR 734 million (4.5%; 1.1% cc) and EUR 134 million (12.5%; 12.1% cc), respectively. Bio Supplies achieves EUR 267 million in ...
-
Endomedix, Inc. to present its innovative technology addressing the needs of Warfighters at the upcoming Military Health System and Research Symposium 2019 annual meeting
Endomedix, Inc., today announced that it will present its patented revolutionary technology to control bleeding in battlefield injuries at the upcoming Military Health System and Research Symposium (MHSRS) annual meeting. Loss of blood still remains the most common cause of potentially preventable deaths in battlefield casualties, two-thirds of such deaths result from truncal hemorrhage that ...
-
Endomedix, Inc. to Present at Upcoming Society For Biomaterials 2019 Annual Meeting
Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you